The Bengaluru‑based startup said the new funding will help it scale manufacturing capacity toward a target of 250,000 electric two‑wheelers annually and take on mainstream competitors.
Bengaluru‑based Ultraviolette Automotive has secured $85 million in fresh capital to accelerate the production of its flagship X‑47 Venom electric sportbike, aiming to expand its manufacturing capacity toward a long‑term goal of 250,000 electric two‑wheelers per year.
Funding round details
The financing, led by a consortium of venture investors, will be deployed to scale up Ultraviolette’s assembly lines, enhance battery sourcing, and broaden its dealer network across India. The company did not disclose the exact valuation, but the influx of funds signals strong investor confidence in its high‑performance EV platform.
Production scaling plans
Ultraviolette plans to upgrade its existing plant in Bengaluru and set up a new facility in the outskirts of the city. The expanded infrastructure is expected to support a modular production approach, allowing the firm to ramp output quickly in response to market demand.
- Increase assembly line capacity to meet a target of 250,000 units annually
- Invest in advanced battery management systems and local cell procurement
- Expand the service and dealer network to major Indian metros
- Accelerate R&D for next‑generation electric sportbike models
Market outlook
The X‑47 Venom enters a rapidly growing electric two‑wheel market, where traditional manufacturers are launching their own EV models. Ultraviolette’s focus on performance and premium branding positions it to compete with both established bike makers and emerging startups.
For readers interested in broader startup trends, explore more stories in the Startups on uxc.news section.
Read the full report in the Financial Express coverage of Ultraviolette funding.
Comments
No comments yet.